Luming Wang, Yangyang Xia, Chenshu Liu, Xiaofeng Shan, Yi Sui, Shang Xie, Zhigang Cai
{"title":"Anti-SIA-cIgG enhances chemotherapy effectiveness through PTPN13-regulated tumor stemness in head and neck squamous cell carcinoma.","authors":"Luming Wang, Yangyang Xia, Chenshu Liu, Xiaofeng Shan, Yi Sui, Shang Xie, Zhigang Cai","doi":"10.1515/jtim-2026-0040","DOIUrl":"https://doi.org/10.1515/jtim-2026-0040","url":null,"abstract":"<p><strong>Background and objectives: </strong>The chemotherapy response rate in head and neck squamous cell carcinoma (HNSCC) remains low due to a lack of effective therapeutic targets, and treatment efficacy is further limited by chemoresistance and heterogeneity in drug response. Sialylated cancer IgG (SIA-cIgG) is a tumor-derived immunoglobulin implicated in tumor stemness. However, the relationship between SIA-cIgG and chemoresistance, and its potential as a therapeutic target, remain to be determined.</p><p><strong>Methods: </strong>We evaluated the antitumor eficacy of SIA-cIgG inhibition combined with four chemotherapeutic agents using two HNSCC cell lines with high or low SIA-cIgG expression, along with in vivo xenograft models. Furthermore, we investigated the functional roles of SIA-cIgG and its downstream effector PTPN13 in regulating HNSCC stemness. Patient-derived organoids (PDOs) from 25 HNSCC patients were used to compare the antitumor eficacy of anti-SIA-cIgG-based combinations against conventional clinical chemotherapy regimens.</p><p><strong>Results: </strong>Elevated SIA-cIgG protein levels correlated positively with an increased IC50 for cisplatin and poorer chemotherapy response. SIA-cIgG/PTPN13 axis was critical for tumor stemness and chemoresistance. Anti-SIA-cIgG treatment enhanced PTPN13 protein stability and upregulated PTPN13 mRNA expression via SP1. Anti-SIA-cIgG-based drug combinations demonstrated significantly higher anticancer efficacy than conventional clinical chemotherapy regimens and overcame tumor heterogeneity in drug response.</p><p><strong>Conclusions: </strong>SIA-cIgG/PTPN13 axis regulates tumor stemness and contributes to chemoresistance, anti-SIA-cIgG-based drug combinations exhibit significant potential for clinical application.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 2","pages":"237-258"},"PeriodicalIF":7.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13110467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147787838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reframing sepsis research through translational integrative models.","authors":"Dandan Zhu, Krzysztof Laudanski","doi":"10.1515/jtim-2026-0017","DOIUrl":"https://doi.org/10.1515/jtim-2026-0017","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"1-5"},"PeriodicalIF":7.4,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916269/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jingya Zhao, Xinning Lu, Hui Wang, Qin Chen, Yigang Wan
{"title":"Associations of the triglyceride-glucose index, triglyceride glucose-body mass index, waist-triglyceride index and modified triglyceride-glucose indices with mortality in cardiovascular-kidney-metabolic syndrome stages 0-4: Evidence from NHANES 1999-2020.","authors":"Jingya Zhao, Xinning Lu, Hui Wang, Qin Chen, Yigang Wan","doi":"10.1515/jtim-2026-0014","DOIUrl":"https://doi.org/10.1515/jtim-2026-0014","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"158-161"},"PeriodicalIF":7.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Association between free fatty acids and adverse outcomes in patients with and without diabetes undergoing percutaneous coronary intervention.","authors":"Qinxue Li, Guyu Zeng, Deshan Yuan, Tianyu Li, Peizhi Wang, Ce Zhang, Sida Jia, Pei Zhu, Ying Song, Xiaofang Tang, Ping Liu, Yuejin Yang, Runlin Gao, Jingjing Xu, Xueyan Zhao, Jinqing Yuan","doi":"10.1515/jtim-2026-0016","DOIUrl":"https://doi.org/10.1515/jtim-2026-0016","url":null,"abstract":"<p><strong>Background and objectives: </strong>This study aimed to explore the correlation between free fatty acid (FFA) levels and adverse outcomes in patients undergoing percutaneous coronary intervention (PCI) with or without diabetes mellitus.</p><p><strong>Methods: </strong>In total, 10,230 patients treated with PCI were included in this study and divided into three equal groups according to FFA levels (FFA-L, FFA-M, and FFA-H groups). Subsequently, the patients were further stratified based on their diabetes status. A 5-year follow-up was conducted, with the primary endpoint defined as major adverse cardiovascular and cerebrovascular events (MACCE).</p><p><strong>Results: </strong>During follow-up, 2108 (20.6%) patients experienced MACCE. In patients without diabetes, no significant difference was observed in the risk of MACCE among the different FFA groups. However, in patients with diabetes, the risk of MACCE was significantly higher in the FFA-L and FFA-H groups than in the FFA-M group [adjusted hazard ratio (HR), 1.238, 95% confidence interval (CI), 1.054-1.454, <i>P</i> = 0.009; adjusted HR: 1.220, 95% CI, 1.054-1.412, <i>P</i> = 0.008; respectively]. The restricted cubic spline curves showed a nonlinear U-shaped relationship between the FFA levels and the risk of MACCE in patients with diabetes, with the lowest risk observed at an FFA level of 372 μmol/L. The results of the subgroup analysis stratified by different clinical presentations and BMI were similar to those of the primary findings.</p><p><strong>Conclusions: </strong>In patients with diabetes undergoing PCI, both elevated and decreased FFA levels were significantly associated with an increased risk of MACCE. Monitoring FFA levels is essential to help identify those at high risk.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"53-63"},"PeriodicalIF":7.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916277/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Feel the force: Biomechanical homeostasis of the cardiovascular system.","authors":"Quanyou Shi, Ming Xu, Chi Zhu, Guoping Shi","doi":"10.1515/jtim-2026-0015","DOIUrl":"https://doi.org/10.1515/jtim-2026-0015","url":null,"abstract":"","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"6-9"},"PeriodicalIF":7.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Migrasome as a novel organelle: Biogenesis, physiological functions, and therapeutic potential.","authors":"Rumeng Tang, Ling Zhou, Jiaran Lin, Xiangyuan Zhang, Pengfei Xie, Lili Zhang, Linhua Zhao, Xiaolin Tong","doi":"10.1515/jtim-2026-0008","DOIUrl":"https://doi.org/10.1515/jtim-2026-0008","url":null,"abstract":"<p><p>Migrasomes are a recently identified type of membranous organelle formed during cell migration. They are produced by migratory cells and widely distributed across various cells and tissues. Migrasomes contain abundant signaling and bioactive molecules, playing crucial roles in embryonic development, angiogenesis, material transport, mitochondrial quality control, and coagulation, as well as participating significantly in numerous pathological processes. This paper provides a detailed overview of the latest advancements in migrasome biology research, including migrasome biogenesis, physiological functions, isolation, and identification, and their roles in the onset, progression, diagnosis, and treatment of clinical diseases. In addition, we propose novel hypotheses and outline future research directions addressing current challenges and potential clinical applications of migrasomes, which may inform their utilization in future clinical diagnostics and therapeutics.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"34-52"},"PeriodicalIF":7.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng
{"title":"Therapeutic potential of TMSC-Exo for non-alcoholic fatty liver disease using the liver-on-a-chip model.","authors":"Shujiao He, Kexin Wang, Binghui Li, Wei Fang, Xinyi Wei, Fen Yao, Nan Wang, Xiaoxia Wang, Ying Zhang, Yi Gao, Yang Li, Shao Li, Shuqin Zhou, Juan Du, Qing Peng","doi":"10.1515/jtim-2026-0007","DOIUrl":"https://doi.org/10.1515/jtim-2026-0007","url":null,"abstract":"<p><strong>Background and objectives: </strong>Non-alcoholic fatty liver disease (NAFLD) has become a growing global public health concern. Effective therapeutic strategies for NAFLD remain urgently needed. Liver-on-a-chip (LC) technology offers an innovative platform for NAFLD modeling and drug development. This study aimed to develop a biomimetic liver-chip using co-cultured human hepatocyte (HepaRG) with hepatic stellate and endothelial cells to model NAFLD, and evaluate the therapeutic potential of scalable telomerase reverse transcriptase (hTERT)-immortalized umbilical cord mesenchymal stem cell-derived exosomes (TMSC-Exo).</p><p><strong>Methods: </strong>HepaRG cells, hepatic stellate cells, and endothelial cells were used to construct a dual-chamber biocompatible LC. The NAFLD model was induced by free fatty acid (FFA) and applied to evaluate the efficacy of resmetirom and TMSC-Exo for the treatment of NAFLD. Moreover, the high-fat (HF) diet-induced mouse model was analyzed to verify the in vitro results. Proteomic analyses were performed to explore the molecular mechanisms involved in the development of NAFLD and the effect of TMSC-Exo in treating NAFLD.</p><p><strong>Results: </strong>Cells cultured in LC showed better viability compared to those in the Transwell system. The on-chip NAFLD model mimicked the characteristics of NAFLD <i>in vivo</i>, including intracellular lipid accumulation and impaired hepatocyte functions in albumin synthesis, levels of urea, CYP1A2, and CYP3A4. Both TMSC-Exo and resmetirom displayed a significant effect in reducing the lipid accumulation in the on-chip NAFLD model. The TMSC-Exo showed superior effects in elevating the levels of albumin, urea, CYP1A2, and CYP3A4. The therapeutic effects of TMSC-Exo were also confirmed in the NAFLD mouse models. Proteomic analysis found that the top 15 up- and down-regulated differentially expressed proteins in NAFLD models compared to the control group were mainly associated with lipid metabolism, endoplasmic reticulum stress, and inflammation.</p><p><strong>Conclusions: </strong>Our on-chip NAFLD model successfully recapitulated key pathological features of hepatic steatosis and functional impairment. Using this model, we evaluated TMSC-Exo and demonstrated its significant therapeutic efficacy against NAFLD.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"14 1","pages":"134-149"},"PeriodicalIF":7.4,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12916270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147272820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}